Interleukin-10-1082G/A polymorphism and acute liver graft rejection: A meta-analysis

Table 1 Baseline characteristics of studies included in the meta-analysis

Ref.	Transplant period	Indications for transplantation	Patients characteristics (age, gender)	Definition of acute rejection	Immunosuppression regimens
Bathgate et al[21]	1992-1998	ALD, PBC, PSC, chronic viral hepatitis, acute liver failure, autoimmune hepatitis, other	Not described	Liver biopsy and treatment with high- dose steroids	CsA/tacrolimus + prednisone + azathioprine
Tambur et al[20]	Not described	Hepatitis B and/or hepatitis C, PBC, PSC, cryptogenic, other	20-69 yr, M/F: 32/36	Liver biopsy (AR within first 6 wk)	CsA/tacrolimus + prednisone with or without azathioprine.
Warlé et al[18]	1992-1999	Hepatitis B, hepatitis C, PBC, PSC, ALD, other	AR group: 47 ± 11 yr, M/F: 22/19 Non-AR group: 49 ± 12 yr, M/F: 20/28	Liver biopsy and treatment with high-dose steroids (AR within first 4 wk)	CsA/tacrolimus + prednisone Maintain target therapeutic blood levels of 100-200 ng/mL for CsA or 5-10 ng/mL for tacrolimus
Fernandes et al[19]	Not described	Not described	19-73 yr, M/F: 26/27	Liver biopsy and treatment with high- dose steroids	Tacrolimus + prednisolone
Mas et al[17]	1999-2000	Hepatitis B, Hepatitis C, PSC, HCC, ALD, Cryptogenic, other	24-60 yr, M/F: 44/33	Liver biopsy (AR within first 8 wk)	CsA/tacrolimus + steroids + MMF
Karasu et al[16]	2002-2003	Viral, nonviral	AR group: 44.4 ± 12.7 yr, M/F: 17/9 Non-AR group: 37.4 ± 11.8 yr, M/F:11/6	Treatment with high-dose steroids (AR within first 8 wk)	CsA/tacrolimus+steroids Maintain target therapeutic blood levels of 5-10 ng/mL for tacrolimus
Xie et al[15]	2003-2005	HBV-related cirrhosis, HBV-related HCC, fulminant hepatitis B	AR group: 43.6 ± 9.0 yr, M/F: 35/6 Non-AR group: 46.5 ± 9.0 yr, M/F:130/15	Liver biopsy (AR within first 4 wk)	CsA/tacrolimus + prednisolone + MMF

ALD: Alcoholic liver disease; PBC: Primary biliary cirrhosis; PSC: Primary sclerosing cholangitis; HCC: Hepatocellular carcinoma; HBV: Hepatitis B viral; CsA: Cyclosporine A; MMF: Mycophenolate mofetil; AR: Acute rejection.

Table 2 Characteristics of studies included in the meta-analysis

Ref.	Country	Ethnicity	No. of	Case		Control		Genotyping methods	HWE in controls
			case/control	AA	AG/GG	AA	AG/GG
Bathgate et al[21]	United Kingdom	Caucasian	68/76	16	52	22	54	PCR-SSP	Yes
Tambur et al[20]	Israel	Caucasian	33/30	19	14	14	16	PCR-SSP	No
Warlé et al[18]	Netherlands	Caucasian	41/48	6	35	17	31	ARMS-PCR	Yes
Fernandes et al[19]	United States	Caucasian	13/40	4	9	15	25	AS-PCR	Yes
Mas et al[17]	United States	Caucasian	19/55	12	7	12	43	DNA-sequencing	Yes
Karasu et al[16]	Turkey	Caucasian	26 /17	12	14	8	9	PCR-SSP	Yes
Xie et al[15]	China	Asian	41/145	36	5	128	17	PCR-RFLP	Yes

PCR-SSP: Polymerase chain reaction and sequence-specific primer typing; ARMS-PCR: Amplification refractory mutation system-polymerase chain reaction; AS-PCR: Allele-specific polymerase chain reaction; PCR-RFLP: Polymerase chain reaction-restriction fragment length polymorphism; HWE: Hardy-Weinberg equilibrium.